<DOC>
	<DOC>NCT02723071</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of ocrelizumab in participants with progressive follicular NHL.</brief_summary>
	<brief_title>A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<criteria>Follicular NHL Documented history of response, or stable disease more than 6 months in duration, to a rituximabcontaining regimen that was the last treatment before enrollment in the study No evidence of hepatitis B or C Prior monoclonal antibody therapy other than rituximab, anticancer vaccine, or radioimmunotherapy for cancer History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies, or known sensitivity or allergy to murine products Major nondiagnostic surgery within 4 weeks of Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>